ʻO ka hāʻule ʻana o ka naʻau me ka haʻihaʻi hoʻokuʻu liʻiliʻi (HFrEF) kahi ʻano nui o ka puʻuwai puʻuwai, a ua hōʻike ka China HF Study he 42% o ka pau ʻana o ka naʻau ma Kina he HFrEF, ʻoiai aia kekahi mau papa lapaʻau maʻamau o nā lāʻau lapaʻau no HFrEF a ua hōʻemi i ka pilikia. o ka make a me ka halema'i no ka pau ole o ka na'au i kekahi wahi.Eia nō naʻe, ʻoi aku ka nui o ka poʻe maʻi i ka hōʻino ʻana o ka naʻau i nā hanana, ʻoi aku ka nui o ka make ma kahi o 25% a ʻilihune ka prognosis.No laila, aia nō kahi koi wikiwiki no nā mea lapaʻau hou i ka mālama ʻana iā HFrEF, a ua aʻo ʻia ʻo Vericiguat, kahi novel soluble guanylate cyclase (sGC) stimulator, i ka noiʻi VICTORIA e loiloi inā hiki iā Vericiguat ke hoʻomaikaʻi i ka wānana o nā maʻi me HFrEF.ʻO ka haʻawina he multicenter, randomized, parallel-group, placebo-controlled, double-blind, event-driven, phase III clinical results study.Hana ʻia ma lalo o ka mana o ka VIGOR Center ma Kanada me ka hui pū me ka Duke Clinical Research Institute, 616 mau kikowaena ma 42 mau ʻāina a me nā ʻāina, me ʻEulopa, Iapana, Kina a me ʻAmelika Hui Pū ʻIa, i komo i ka noiʻi.Hoʻohanohano ʻia kā mākou ʻoihana cardiology e komo.ʻO ka huina o 5,050 mau mea maʻi me ka maʻi puʻuwai maʻi mau makahiki ≥18 makahiki, NYHA papa II-IV, EF <45%, me nā kiʻekiʻe o ka natriuretic peptide (NT-proBNP) kiʻekiʻe i loko o 30 mau lā ma mua o ka randomization, a i hoʻopaʻa ʻia i ka hale maʻi no ka pau ʻole o ka naʻau. i loko o 6 mau mahina ma mua o ka randomization a i ʻole nā diuretics i lawelawe ʻia ma ka intravenously no ka pau ʻole o ka naʻau i loko o 3 mau mahina ma mua o ka randomization ua kākau inoa ʻia i loko o ke aʻo ʻana, nā mea a pau e loaʻa ana i ka ESC, AHA/ACC, a me nā alakaʻi kikoʻī ʻāina / ʻāina i ʻōlelo ʻia i ke kūlana mālama.Ua hoʻokaʻawale ʻia nā maʻi ma kahi ratio 1: 1 i ʻelua mau pūʻulu a hāʻawi ʻiaVericiguat(n=2526) a me kahi placebo (n=2524) ma luna o ka lāʻau lapaʻau maʻamau.
ʻO ka hopena mua o ke aʻo ʻana ʻo ia ka hopena composite o ka make cardiovascular a i ʻole ka hoʻokipa mua ʻana o ka naʻau;ʻO nā helu hope lua i komo nā ʻāpana o ka hopena mua, nā hale maʻi hōʻino naʻau mua a ma hope (nā hanana mua a me nā hanana hou), ka helu hope o nā kumu āpau a i ʻole ka hoʻomaha ʻana i ka naʻau, a me nā kumu make.Ma kahi median follow-up o 10.8 mahina, aia he 10% ka emi ʻana o ka hopena mua o ka make cardiovascular a i ʻole ka hoʻokipa mua ʻana o ka naʻau ma ka hui Vericiguat i hoʻohālikelike ʻia me ka hui placebo.
ʻO ka hōʻikeʻana i nā hopena hope loa i hōʻikeʻia i ka emi nui o ka hoʻomahaʻana o ka naʻau (HR 0.90) a me ka hoʻohaʻahaʻa nuiʻana i ka hopena composite o nā kumu a pau o ka make a me ka hoʻomahaʻana o ka naʻau (HR 0.90) i ka hui Vericiguat i hoʻohālikelikeʻia me ka hui placebo.
Hōʻike nā hopena o ka haʻawina i ka hoʻohui ʻana oVericiguatʻO ka hoʻomaʻamaʻa maʻamau o ka hāʻule ʻana o ka naʻau e hōʻemi nui i ka hiki ʻana mai o nā hanana ʻino o ka naʻau a hōʻemi i ka hopena o ka hopena composite o ka make ʻana o ka naʻau a i ʻole ka hoʻokipa ʻana no ka hōʻeha puʻuwai i nā maʻi me HFrEF.ʻO ka hiki o Vericiguat ke hōʻemi i ka hopena o ka hopena composite o ka make cardiovascular a i ʻole ka hoʻomaha ʻana i ka naʻau i ka haukapila i nā mea maʻi me ka puʻuwai puʻuwai kiʻekiʻe e hāʻawi i kahi ala therapeutic hou no ka puʻuwai puʻuwai a wehe i nā ala hou no ka ʻimi ʻana i ka maʻi cardiovascular.ʻAʻole ʻae ʻia ʻo Vericiguat no ke kūʻai aku ʻana.Pono e hoʻāʻo hou ʻia ka palekana, ka maikaʻi a me ke kumukūʻai o ka lāʻau lapaʻau ma ka mākeke.
Ka manawa hoʻouna: Feb-09-2022